The weight loss medication landscape is experiencing an unprecedented wave of innovation. With 39 new GLP-1-related medications currently in development, the options available to patients are about to expand dramatically. Here’s a comprehensive look at every major drug in the pipeline, from the ones launching this year to the experimental therapies that could arrive by 2028.
Already Available or Launching in 2026
Oral Wegovy (Semaglutide 25mg Pill) — Available Now
The first oral GLP-1 for weight loss launched in January 2026. It showed 16.6% mean weight loss in the OASIS 4 trial, comparable to the injectable version. Starting dose available at $149/month self-pay. Our oral vs injectable comparison breaks down which form is right for you.
Orforglipron (Eli Lilly) — Expected Spring 2026
A non-peptide oral GLP-1 with no food or water restrictions. Showed ~11% weight loss on the highest dose, plus maintenance data from ATTAIN-MAINTAIN. FDA decision expected by March 2026. Full details in our orforglipron explainer.
Wegovy 7.2mg (Higher Injection Dose) — Under FDA Review
A higher dose of injectable semaglutide (7.2mg vs the current 2.4mg maximum) showed approximately 19% mean body weight loss in the STEP UP trial, with treatment completers achieving nearly 21%. This would bring semaglutide’s efficacy much closer to tirzepatide’s range.
Key stat: Wegovy 7.2mg showed ~19% weight loss in the STEP UP trial — a significant improvement over the current 2.4mg dose’s ~15%.
CagriSema (Novo Nordisk) — Expected 2026
Combines semaglutide with cagrilintide (an amylin analog) in a dual-chambered once-weekly injection. Showed ~20% weight loss at 68 weeks (~23% for completers). Submitted to FDA December 2025. Full coverage in our CagriSema deep dive.
Late-Stage Pipeline (Phase 3 / FDA Filing Expected)
Retatrutide (Eli Lilly) — Triple Agonist
Perhaps the most anticipated pipeline drug, retatrutide targets three receptors simultaneously: GLP-1, GIP, and glucagon. Phase 2 data showed up to 24% body weight loss at 48 weeks — the highest ever reported for a single-agent obesity medication. Phase 3 trials are ongoing, with FDA submission expected in 2026-2027. If the phase 3 results hold, retatrutide could reset the efficacy ceiling for the entire class.
Survodutide (Boehringer Ingelheim) — Dual Agonist
A dual GLP-1/glucagon receptor agonist. Phase 3 results are pending, with the compound showing promising earlier-stage data for both obesity and MASH (liver disease). The glucagon component may offer unique metabolic benefits, including improved fat oxidation and energy expenditure.
Viking Therapeutics VK2735 — Dual Agonist
Another dual GIP/GLP-1 agonist from a smaller biotech company, with oral and injectable formulations in development. Early data showed 14.7% weight loss at 13 weeks (a very short trial), suggesting strong efficacy. Viking is pursuing both subcutaneous and oral versions simultaneously.
Muscle-Sparing Combinations (Experimental)
Bimagrumab + Semaglutide
Bimagrumab is a myostatin inhibitor — it blocks the signals that cause muscle breakdown. In a study of bimagrumab alone, patients lost 6.5% of body weight but gained 3.6% lean mass while losing 20.5% fat mass. Combining it with semaglutide could potentially solve the muscle loss concern entirely. Primate studies of semaglutide combined with anti-myostatin antibodies showed large fat loss with simultaneous lean mass preservation.
Trevogrumab + Garetosmab + Semaglutide
Novo Nordisk is testing a triple combination: semaglutide for weight loss, trevogrumab (anti-myostatin) for muscle preservation, and garetosmab (anti-activin A) for additional muscle-sparing effects. Early primate data is encouraging. This represents the cutting edge of “precision obesity medicine” — losing fat while actively preserving or building muscle.
New Indications for Existing Drugs
Beyond new molecules, existing GLP-1 medications are being studied for conditions well beyond weight loss:
Heart failure (HFpEF): Wegovy is under FDA review for heart failure with preserved ejection fraction, a condition strongly linked to obesity.
Peripheral artery disease (PAD): Ozempic is under FDA review for PAD, with studies showing improved walking distance and quality of life.
Alzheimer’s disease: Multiple GLP-1 medications are being studied for neuroprotective effects. Early research is promising but still in earlier stages.
Addiction: Emerging research suggests GLP-1 receptor activation may reduce cravings for alcohol and other substances. Clinical trials are underway.
For the cardiovascular benefits already proven, see our article on GLP-1 heart health benefits.
Ready to start now? Compare telehealth providers offering currently available GLP-1 medications with licensed physicians and home delivery.
Compare Providers →What This Means for You
The pace of innovation in obesity medicine is unlike anything we’ve seen before. Within the next 2-3 years, patients will have access to pills with no dietary restrictions, triple-agonist injections approaching surgical-level weight loss, and combination therapies that preserve muscle while eliminating fat. If you’re waiting for the “perfect” medication, the pipeline suggests it’s getting closer — but the medications available today are already highly effective, and starting now builds the habits and health foundation that will make any future transition easier.